TORONTO, July 3, 2024 /CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust") announces that it will hold a conference call to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024, at 8:00 a.m. ET. The Trust will report its financial results on Tuesday, August 6, 2024, after market close.

All interested parties may join the conference call by dialling 416-764-8659 or 1-888-664-6392 approximately 15 minutes prior to the call to secure a line. You will be put on hold until the conference call begins. To join the conference call without operator assistance, you may register and enter your phone number at https://emportal.ink/3zk9Ebc to receive an instant automated callback. A question-and-answer session will follow management's prepared remarks, at which time the operator will provide instructions for qualified equity analysts to submit questions.

A live webcast of the conference call, including a slide presentation, will be available at https://app.webinar.net/MAxX169nQNb. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on the Trust's website following the call date.

About DRI Healthcare Trust

DRI Healthcare Trust is managed by DRI Capital Inc. ("DRI Healthcare"), the pioneer in global pharmaceutical royalty monetization with a 35-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since its founding in 1989, DRI Healthcare has deployed more than US$3.0 billion, acquiring more than 70 royalties on 45-plus drugs, including Eylea, Keytruda, Orserdu, Spinraza, Stelara, Vonjo, Zejula and Zytiga. DRI Healthcare Trust's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U". To learn more, visit drihealthcare.com or follow us on LinkedIn.

SOURCE DRI Healthcare Trust

View original content: https://www.newswire.ca/en/releases/archive/July2024/03/c0322.html